Overview

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.

Phase:

Phase 2

Details

Lead Sponsor:

ImmunoVaccine Technologies, Inc. (IMV Inc.)

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Cyclophosphamide
Pembrolizumab